

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Los Angeles, California, United States
Aurora, Colorado, United States
Decatur, Georgia, United States
Grand Rapids, Michigan, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Fairfax, Virginia, United States
Milwaukee, Wisconsin, United States
Parkville, Victoria, Australia
Perth, West Australia, Australia
Vienna, , Austria
Edegem, , Belgium
Sao Paulo, , Brazil
Copenhagen, , Denmark
Garches, , France
Lille, , France
Firenze, , Italy
Niigata, , Japan
Osaka, , Japan
Osaka, , Japan
Tokyo, , Japan
Cambridge, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Salford, , United Kingdom

Study to compare the efficacy and safety of migalastat and enzyme replacement therapy (ERT) in male and female participants with Fabry disease who are currently receiving ERT and who have an alpha galactosidase-A (α Gal-A) mutation that is amenable to migalastat, based on the clinical trial human embryonic kidney cell (HEK) assay.